Resources

Out of Step: TB policies in 29 countries, 3rd Ed. (2017)

September 19, 2017

Although it can be prevented and successfully treated, tuberculosis (TB) is the world’s deadliest infectious disease: in 2015, 1.8 million people died from it. While there have been substantial and important innovations in the fight against TB, including faster, more accurate diagnostic tests and the first new medicines in nearly 50 years, deadly gaps remain in implementing and providing access to these advances.

eLearning modules

July 14, 2017
​​​​​​The following eLearning units have been developed to provide guidance to physicians caring for MDR-TB patients enrolled in the endTB project.

endTB Clinical Guide v3.3

May 15, 2017

This guide is a draft version designed to give guidance to the endTB Project site on the use of new TB drugs bedaquiline and delamanid.

It is intended to be a resource for physicians and other health care professionals involved in the endTB project.

Terms of reference: endTB Medical Committee

May 13, 2017

The endTB Medical Committee formulates recommendations for off-label and compassionate use of the new anti-TB drugs for M(X)DR-TB.

It provides advice to any MSF, PIH and IRD projects for individual patient’s management on a case-by-case basis in answer to requests initiated by clinicians from the projects.

For more information, please download the terms of reference.

Pharmacovigilance

June 27, 2016

Pharmacovigilance forms and other resources for staff on endTB sites.

endTB: Project presentation

June 27, 2016

This 20-page guide is designed to provide all endTB stakeholders with a detailed presentation of the project's four goals.

DR-TB Drugs Under the Microscope: 4th edition

March 21, 2016

This MSF Access Campaign report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.

We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.

This report was produced with endTB's support.

PIH MSF MSF UNITAID